Eyepoint Pharmaceuticals, Inc.
Clinical trials sponsored by Eyepoint Pharmaceuticals, Inc., explained in plain language.
Develops ophthalmic therapies for eye diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New eye drug aims to cut injection frequency for wet AMD patients
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 people with wet AMD will receive either EYP-1901 or standard aflibercept injections over 2 years. The main goal is to see …
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New eye drug could slash injection frequency for wet AMD patients
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 participants will receive either EYP-1901 or the standard drug aflibercept. The goal is to see if EYP-1901 can maintain or…
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC